Treatment for glioblastoma (GBM)
This site is intended for US healthcare professionals only.
Optune® Novocure™

The NovoTAL System

Optimize treatment with Optune (TTFields) using the FDA‐approved NovoTAL System

The NovoTAL System helps you optimize treatment planning for your patients

  • In electric field simulation studies, it was possible to achieve a substantial increase in Tumor Treating Fields (TTFields) intensity to a specific region of the brain by adapting the configuration of paired arrays1

  • Benefits of performing treatment planning for your Optune patients using the NovoTAL System may include:

    • Direct TTFields intensity to the region of active tumor at your clinical discretion2

    • Better correlation of radiographic findings based on your knowledge of the patient’s treatment history and current clinical status2

    • Adapt your patient’s treatment plan by re-mapping if there are significant changes in tumor imaging over time2

Individualize Optune for every patient

  • Treatment planning is an essential component of therapy with Optune

  • The NovoTAL System is utilized to create individualized treatment maps for all clinical and commercial patients starting Optune

The NovoTAL System is supported by reimbursement, technical and training services

  • Treatment mapping with the NovoTAL System is performed as an in-office procedure

    • Novocure™ Reimbursement Services works directly with you and your staff to assist you throughout the reimbursement process

    • The NovoTAL System is licensed by Novocure to certified physicians, with set-up provided

    • Optune certified physicians are required to complete training and certification in order to use the NovoTAL System

To learn more about the NovoTAL System please email

NovoTAL system transducer array layout
NovoTAL system view form

References:1. Wenger C, Salvador R, Basser PJ, Miranda PC. Improving Tumor Treating Fields treatment efficacy in patients with glioblastoma using personalized array layouts [published online December 14, 2015]. Int J Radiat Oncol Biol Phys . 2015: 2. Chaudhry A, Benson L, Varshaver M, et al. NovoTTF™‐100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL™ System user study. World J Surg Oncol. 2015;13:316. doi:10.1186/s1­2­9­5­7­‐­0­1­5­‐­0­7­2­2­‐­3. 3. NovoTAL User Manual QSD‐QR‐700 Revision 1.4. Novocure January 2015.

How Optune works

See how Tumor Treating Fields (TTFields) disrupt mitosis and inhibit tumor growth.

Watch video

Review user study results

Examine clinical outcomes from a NovoTAL™ System user study.

See the Data


*The NCCN defines good performance as Karnofsky Performance Score (KPS) ≥60. The trial for which the IFU is based used an eligibility criteria of KPS ≥70.
The NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

For the treatment of recurrent GBM, Optune is indicated following histologically- or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

Important Safety Information


Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure (the device manufacturer).

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

The most common (10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

The most common (10%) adverse events seen with Optune monotherapy were medical device site reaction and headache.

The following adverse reactions were considered related to Optune when used as monotherapy: medical device site reaction, headache, malaise, muscle twitching, fall and skin ulcer.

Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.

If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment.

Please click here to see the Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

On this site, patient and healthcare professional videos as well as all images labeled as Optune users, caregivers, or healthcare professionals depict actual patients, caregivers, and healthcare professionals. All other depictions of patients and caregivers are actor portrayals.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).